- Home
- FBK vs VRNA Comparison
FBK vs VRNA Comparison
Compare FBK & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBK
- VRNA
- Stock Information
- Founded
- FBK 1906
- VRNA 2005
- Country
- FBK United States
- VRNA United Kingdom
- Employees
- FBK N/A
- VRNA N/A
- Industry
- FBK Major Banks
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- FBK Finance
- VRNA Health Care
- Exchange
- FBK Nasdaq
- VRNA Nasdaq
- Market Cap
- FBK 2.6B
- VRNA 2.9B
- IPO Year
- FBK 2016
- VRNA 2017
- Fundamental
- Price
- FBK $55.17
- VRNA $37.86
- Analyst Decision
- FBK Hold
- VRNA Strong Buy
- Analyst Count
- FBK 6
- VRNA 6
- Target Price
- FBK $47.33
- VRNA $43.83
- AVG Volume (30 Days)
- FBK 182.0K
- VRNA 1.1M
- Earning Date
- FBK 01-14-2025
- VRNA 11-04-2024
- Dividend Yield
- FBK 1.23%
- VRNA N/A
- EPS Growth
- FBK N/A
- VRNA N/A
- EPS
- FBK 2.30
- VRNA N/A
- Revenue
- FBK $436,397,000.00
- VRNA $5,624,000.00
- Revenue This Year
- FBK N/A
- VRNA N/A
- Revenue Next Year
- FBK $10.52
- VRNA $554.09
- P/E Ratio
- FBK $24.13
- VRNA N/A
- Revenue Growth
- FBK N/A
- VRNA 1127.95
- 52 Week Low
- FBK $32.10
- VRNA $11.39
- 52 Week High
- FBK $58.88
- VRNA $40.13
- Technical
- Relative Strength Index (RSI)
- FBK 60.24
- VRNA 57.91
- Support Level
- FBK $53.73
- VRNA $34.51
- Resistance Level
- FBK $58.88
- VRNA $40.13
- Average True Range (ATR)
- FBK 1.72
- VRNA 2.27
- MACD
- FBK -0.12
- VRNA -0.16
- Stochastic Oscillator
- FBK 67.32
- VRNA 73.40
About FBK FB Financial Corporation
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.